Advances of pathological complete response after neoadjuvant therapy for pancreatic cancer

Abstract. Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a poor prognosis. Only 15% to 20% of patients present with a primarily resectable tumor at the time of diagnosis. There has been an increasing interest in the use of neoadjuvant chemotherapy alone or combination with...

Full description

Bibliographic Details
Published in:	Journal of Pancreatology
Main Authors:	Lingdi Yin, MD, Yi Miao, MD, PhD, Jun Yu, MD, PhD
Format:	Article
Language:	English
Published:	Wolters Kluwer Health/LWW 2019-03-01
Online Access:	http://journals.lww.com/10.1097/JP9.0000000000000009

Similar Items

Adjuvant Chemotherapy After Neoadjuvant Therapy and Surgery for Non-Small Cell Lung Cancer
by: Ryo Miyata, MD, PhD, et al.
Published: (2024-09-01)

Pretreatment MRI Parameters and Neutrophil-to-Lymphocyte Ratio Could Predict the Long-Term Prognosis of Locally Advanced Rectal Cancer Patients With Pathological Complete Response after Neoadjuvant Chemoradiotherapy
by: Yujun Cui MD, et al.
Published: (2025-04-01)

Complete pathological response after neoadjuvant therapy in patients with rectal adenocarcinoma
by: E.A. SÃ¡nchez-PÃ©rez, et al.
Published: (2017-10-01)

Surgical Outcomes Following Neoadjuvant Treatment for Locally Advanced and Borderline Resectable Pancreatic Ductal Adenocarcinoma
by: Kai Tai Derek Yeung, PhD, FRCS, et al.
Published: (2024-09-01)

Giant pancreatic stentolith after chronic transgastric pancreatic duct drainage
by: Kazuki Hama, MD, et al.
Published: (2025-06-01)

Clinical Outcomes of Proton Beam Therapy for Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Retrospective Study
by: Ichiro Seto, MD, DMD, PhD, et al.
Published: (2024-10-01)

Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade
by: David M. Miller, MD, PhD, et al.
Published: (2017-09-01)

A “Just Enough” Gross Proximal Margin Length Ensuring Pathologically Complete Resection in Distal Gastrectomy for Gastric Cancer
by: Masaru Hayami, MD, PhD, et al.
Published: (2020-12-01)

Cytokeratin 7 Expression and Mismatch Repair Status for Survival Prediction in Patients With Low Rectal Cancer After Neoadjuvant Therapy
by: Songli Shi, et al.
Published: (2023-11-01)

Phase 1 Study of Neoadjuvant Short-Course Radiation Therapy Concurrent With Infusional 5-Fluorouracil for the Treatment of Locally Advanced Rectal Cancer
by: Emma C. Fields, MD, et al.
Published: (2019-10-01)

A Robotic Left Lower Lobe Sleeve Lobectomy With Bronchoplasty Using the Fissureless Technique After Neoadjuvant Immunochemotherapy
by: Hitoshi Igai, MD, PhD, et al.
Published: (2026-06-01)

Successful EUS-guided nondilated pancreatic duct stent placement in patient with refractory pancreatic fistula after pancreaticoduodenectomy
by: Kazuhiro Minami, MD, et al.
Published: (2017-11-01)

Predictive factors of pathological complete response after neoadjuvant therapy for locally advanced rectal cancer
by: LI Hao, LUO Yang, WANG Tingfeng, LIN Haiping, GONG Tingyue, ZHAO Yongheng, ZHONG Ming
Published: (2025-01-01)

Sleeve Lobectomy After Neoadjuvant Chemoimmunotherapy Versus Chemotherapy for Squamous Cell Lung Cancer: A Multicenter, Retrospective Study
by: Tianxiang Chen, MD, PhD, et al.
Published: (2023-04-01)

Prediction of T Stage of Rectal Cancer After Neoadjuvant Therapy by Multi-Parameter Magnetic Resonance Radiomics Based on Machine Learning Algorithms
by: Tingting Nie MD, et al.
Published: (2024-12-01)

A Predictive Model to Evaluate Pathologic Complete Response in Rectal Adenocarcinoma
by: Shuiwang Qing MD, et al.
Published: (2023-09-01)

Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer
by: Angela Pennisi, et al.
Published: (2016-07-01)

Relevance of Pathological Complete Response after Neoadjuvant Therapy for Breast Cancer
by: Angela Pennisi, et al.
Published: (2016-01-01)

Severity of Pancreatic Leak in Relation to Gut Restoration After Pancreaticoduodenectomy
by: Vasileios Smyrniotis, MD, PhD, et al.
Published: (2022-06-01)

CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC
by: Jay M. Lee, MD, et al.
Published: (2025-08-01)

Long-term response of vulvar mucosal melanoma treated with neoadjuvant nivolumab
by: Margaux Dubus, MD, et al.
Published: (2023-08-01)

Perspective of neo-adjuvant/conversion and adjuvant therapy for pancreatic neuroendocrine tumors
by: Luohai Chen, MD, PhD, et al.
Published: (2019-09-01)

Complete response of metastatic cutaneous squamous cell carcinoma and multiple locally advanced basal cell carcinomas with concomitant pembrolizumab and sonidegib therapy
by: Carlos González-Cruz, MD, et al.
Published: (2024-04-01)

Neoadjuvant Chemoradiotherapy Upregulates the Immunogenicity of Cold to Hot Tumors in Esophageal Cancer Patients
by: Yushi Nagaki, MD, PhD, et al.
Published: (2024-03-01)

Advanced multiparametric MRI and FDG-PET/CT in multinodular and vacuolating neuronal tumor: A pathologically confirmed case
by: Seiya Kishi, MD, et al.
Published: (2023-09-01)

Correspondence Regarding “Sleeve Lobectomy After Neoadjuvant Chemoimmunotherapy Versus Chemotherapy for Squamous Cell Lung Cancer: A Multicenter, Retrospective Study”
by: Kazuki Takada, MD, PhD, et al.
Published: (2023-08-01)

Integrated Cancer Treatment in the Course of Metastatic Pancreatic Cancer: Complete Resolution in 2 Cases
by: Massimo Bonucci MD, et al.
Published: (2018-09-01)

Complete and Durable Response After Radiation Therapy to Primary Tumor Site of a Patient With Metastatic Anorectal Mucosal Melanoma With Oligoprogression on Nivolumab
by: David G. Wallington, MS, et al.
Published: (2020-05-01)

Relationship Between Pathologic T1 Categories and Pathologic Factors Affecting Prognosis in Pulmonary Adenocarcinoma
by: Hironori Ninomiya, MD, PhD, et al.
Published: (2022-04-01)

How Much Was the Elective Lymph Node Region Covered in Involved-Field Radiation Therapy for Locally Advanced Pancreatic Cancer? Evaluation of Overlap Between Gross Target Volume and Celiac Artery–Superior Mesenteric Artery Lymph Node Regions
by: Rei Umezawa, MD, PhD, et al.
Published: (2020-05-01)

Radiomic Analysis of MRI for Assessing Response to Neoadjuvant Chemoradiotherapy in Rectal Adenocarcinoma: A Systematic Review and Metaanalysis
by: Murat Jakipov MD, MSc, PhD, et al.
Published: (2026-06-01)

Patterns of Failure in Patients With Borderline Resectable/Locally Advanced Pancreatic Cancer After Preoperative Chemotherapy and Stereotactic Body Radiation Therapy
by: Eric M. Chung, MD, MS, et al.
Published: (2024-05-01)

Neoadjuvant Chemoimmunotherapy versus Neoadjuvant Chemoradiotherapy versus Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma: A Real-World, Three-Arm, Retrospective Cohort Study from the Chinese National Cancer Center
by: Long Zhang MD, et al.
Published: (2026-06-01)

Technical options in surgery for artery-involving pancreatic cancer: Invasion depth matters
by: Yi Miao, MD, PhD, et al.
Published: (2023-03-01)

Clinical outcomes and prognostic factors in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy followed by surgery and postmastectomy radiation therapy in the modern treatment era
by: Naomi Nakajima, MD, PhD, et al.
Published: (2018-07-01)

Completeness and Mismatch of Patient-Important Outcomes After Trauma
by: Arthur James, MD, MSc, et al.
Published: (2022-12-01)

A case of improved quality of life in a patient with inoperable pancreatic cancer after repeated RFA
by: Nino Toria, MD, et al.
Published: (2022-10-01)

Preoperative Biliary Drainage Does Not Independently Reduce Survival After Pancreaticoduodenectomy Among Patients With Pancreatic Ductal Adenocarcinoma
by: Karin Johansen, MD, et al.
Published: (2021-09-01)

Monitoring of Circulating Tumor DNA and Indication of De-Escalation Adjuvant Targeted Therapy for EGFR-Mutated NSCLC After Complete Resection
by: Song Dong, PhD, et al.
Published: (2025-01-01)

Cardiac resynchronization therapy via transvenous approach in a 2-year-old boy with a complete atrioventricular block after a tetralogy of Fallot repair
by: Hisaaki Aoki, MD, PhD, et al.
Published: (2017-12-01)